Date(s) - Fri 02/20/2015
12:00 pm - 1:15 pm
The Supreme Court significantly changed the law of patent eligibility in the landmark decisions of Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013) and Alice Corp Pty Ltd v CLS Bank International, 134 S. Ct. 2347 (2014). In this presentation, two leading patent attorneys will address developments in the law of patent eligibility since these decisions and questions that remain to be answered.
Click here to register now.
William (Bill) Gaede is a partner in the law firm of McDermott Will & Emery LLP. Bill focuses his practice on intellectual property litigation in the life sciences and medical device industries. Bill’s practice further focuses on risk management for companies addressing freedom to operate issues. He serves as lead counsel for a wide range of companies and research institutes and has experience with genomics, proteomics, small molecule and protein therapeutics, antibodies, diagnostics, formulations and devices.
Fabio Marino is a partner in the law firm of McDermott Will & Emery LLP. He focuses his practice on intellectual property matters, including patent infringement litigation, strategy and counseling, particularly in the area of computer related technologies. Fabio has technical experience in a variety of areas, including computer networks, telecommunications, software engineering, e-commerce, entertainment and internet-related technologies, computer architecture, digital circuit design, parallel computing, 3D graphics and animation, medical imaging and artificial intelligence.
Location: Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105
Price and Registration
|Ticket Type||Price (Before Ticketing Fees)|
|In-Person In-House Counsel||Free|
|In-Person SFIPLA Member (Law Firm)||$35|
Thanks to Morgan Lewis for sponsoring this meeting and providing a conference room.
Photo credit of micropipette: Wikimedia